ESA reduce the BNP levels, NYHA class, and hospitalization rates in patients with cardio-renal anemia syndrome, so the correction of anemia by ESA plays a role in the improvement of the clinical outcome in this subset of patients with heart failure [8]. Here, NPPB is linked to anemia (phenotype).